Breakthrough Malaria Vaccine Receives WHO Approval: A Milestone in Global Health

▴ malaria vaccine
Adar Poonawalla, CEO of Serum Institute of India, highlighted the potential of the vaccine to save lives in malaria-stricken regions of Africa and acknowledged the WHO for its pivotal role in reaching this significant milestone

In a significant stride towards combatting malaria, the World Health Organization (WHO) has recommended the use of the R21/Matrix-M malaria vaccine, developed collaboratively by the University of Oxford and the Serum Institute of India (SII). This development marks a crucial milestone in the ongoing efforts to address the impact of malaria, particularly in regions where the disease is endemic.

The Combined Efforts: Adar Poonawalla, CEO of Serum Institute of India, expressed gratitude for the achievement, emphasizing the joint efforts of both institutions. He highlighted the potential of the vaccine to save lives in malaria-stricken regions of Africa and acknowledged the WHO for its pivotal role in reaching this significant milestone.

Vaccine Recommendation by WHO: Following a comprehensive review by the WHO's independent advisory bodies, the Strategic Advisory Group of Experts (SAGE) and the Malaria Policy Advisory Group (MPAG), the R21/Matrix-M malaria vaccine has received a formal recommendation for use. The decision was based on extensive pre-clinical and clinical trial data, demonstrating the vaccine's safety and high efficacy in multiple countries with varying malaria transmission patterns.

Key Features of the R21/Matrix-M Malaria Vaccine:
1. World's Second WHO-Recommended Malaria Vaccine: The R21/Matrix-M vaccine is now the second WHO-recommended vaccine for preventing malaria in children. Its approval is a testament to its effectiveness and potential impact.

2. Global Licensing and Usage: The vaccine has been licensed for use in Ghana, Nigeria, and Burkina Faso, marking a crucial step in making this breakthrough technology accessible in regions heavily burdened by malaria.

3. Promising Clinical Trial Results: The Phase III clinical trial, encompassing 4,800 children across Burkina Faso, Kenya, Mali, and Tanzania, has shown promising results. The data is currently undergoing peer review before publication.

4. Collaborative Development: Developed by the Jenner Institute at Oxford University and Serum Institute of India, the vaccine's journey involved support from organizations such as the European and Developing Countries Clinical Trials Partnership ('EDCTP'), the Wellcome Trust, and the European Investment Bank ('EIB').

Potential Impact: The approval of the R21/Matrix-M malaria vaccine opens new doors in the fight against malaria, especially in regions where the disease poses a significant health threat. In combination with existing public health measures like insecticide-treated bed nets, this vaccine has the potential to save and improve the lives of millions of children and their families.

Next Steps: With the WHO recommendation in place, additional regulatory approvals are anticipated to follow suit. The Serum Institute of India anticipates that the vaccine doses could be ready for a wider rollout as early as the coming year.

The approval of the R21/Matrix-M malaria vaccine by the WHO signals a breakthrough in malaria prevention and underscores the significance of global collaborations in addressing pressing healthcare challenges. As the world eagerly awaits the wider deployment of this vaccine, its potential to make a substantial impact on malaria-related mortality becomes a ray of hope in the realm of global health

Tags : #malaria #vaccine #AdarPoonawalla #seruminstitute #WHO #R21MATRIXM #medicircle

About the Author


Sunny Parayan

Hey there! I'm Sunny, a passionate writer with a strong interest in the healthcare domain! When I'm not typing on my keyboard, I watch shows and listen to music. I hope that through my work, I can make a positive impact on people's lives by helping them live happier and healthier.

View Profile

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Top 4 IVF Centres for High Success RatesJune 24, 2025
Former President Ram Nath Kovind to Inaugurate National Conference of CA Students 2025 in KolkataJune 24, 2025
Bollywood actor Salman Khan says he is suffering from a brain aneurysm, what you need to know about the conditionJune 24, 2025
Butterfly Unveils a Bold New Identity That Celebrates Change and Champions the Original YouJune 24, 2025
8 Daily Habits to Keep Arthritis at BayJune 24, 2025
Food Safety and Drug Administration (FDA), Goa, National Association of Street Vendors of India (NASVI) and Nestlé India expand Project ‘Serve Safe Food’ in GoaJune 24, 2025
Top 4 Startups Driving Credit Risk Innovation in India’s Healthcare and Pharma SectorJune 24, 2025
Sova Health to Host a Free Masterclass on World Microbiome Day, Demystifying Digestive HealthJune 24, 2025
Doctor-Approved Hacks for Better Sleep TonightJune 24, 2025
Indian Assistive Technology Pioneer Prateek Madhav Champions Global Disability Tech Reform with The Royal Society of London Report LaunchJune 24, 2025
Wow! Momo Launches India’s First Gluten-Free Range of Momos – A Game-Changer for Health Conscious FoodiesJune 24, 2025
Medicolegal Risks in TelemedicineJune 24, 2025
Digital Mental Health Clinics in Tier-2 CitiesJune 24, 2025
AssisTech Foundation Hosts Inclusive Job Festival for Persons with DisabilitiesJune 23, 2025
Travel with Ease: Why Congestion Patches Are the Smart Traveler’s Secret WeaponJune 23, 2025
Paper-Tech Platform Paper Arizona Hits ₹100 Cr Annual Revenue Milestone, Eyes IPO Listing in 2026June 23, 2025
Eat Better to enhance its Quick Commerce Operations with UnicommerceJune 23, 2025
Stahl Unveils Blacksmith Signature Cast Iron Tawas: A Classic Essential with a Modern Update for Timeless Indian KitchensJune 23, 2025
Lilly’s once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trialsJune 23, 2025
Finding strength in struggle for gender equality and human rightsJune 23, 2025